2026-02-18 - CoA - Amgen v. Sanofi et al. - UPC_CoA_528/2024 UPC_CoA_529/2024
- Aktenzeichen:
- UPC_CoA_528/2024 UPC_CoA_529/2024
- Datum:
- Spruchkörper:
- Court of Appeal - Luxembourg (LU)
- Art:
- Order
- Parteien:
- SANOFI-AVENTIS DEUTSCHLAND GMBH, SANOFI-AVENTIS GROUPE S.A., SANOFI WINTHROP INDUSTRIE S.A., and Regeneron Pharmaceuticals Inc. v. AMGEN, INC
Kernaussage: The CoA rejected Sanofi/Regeneron's application for suspensive effect of their rehearing application against the CoA's 25 November 2025 decision (which set aside CFI Munich's revocation of EP 3 666 797).
2026-02-18 - CoA - Amgen
v.
Sanofi et al. - UPC_CoA_528/2024 UPC_CoA_529/2024
notable
The CoA rejected Sanofi/Regeneron's application for suspensive effect of their rehearing application against the CoA's 25 November 2025 decision (which set aside CFI Munich's revocation of EP 3 666 797). The CoA held that (1) the applicants failed to provide any specific argument for suspensive effect beyond their rehearing arguments, and (2) there was nothing to suspend — since the appeal against the CFI's revocation had automatic suspensive effect under Art. 74(2) UPCA, the patent remained valid throughout, and the CoA's decision rejecting revocation did not modify the patent's status.